C-P9VZADvantage Therapeutics
immunomodulation, Klotho mRNA, neurodegeneration
modulatingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-P9VZ
C-P9VZC-P9VZimmunomodulation, Klotho mRNA, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ADvantage Therapeutics immunomodulation, Klotho mRNA, neurodegeneration
ADvantage Therapeutics is developing novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s disease. Its lead therapeutic, AD04™, is described as an immuno-stimulant with disease-modifying potential in early Alzheimer’s disease. The company also describes Klotho-based longevity programs hosted by its spinoff, Klothea Bio Inc.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
ADvantage Therapeutics — Translational · Lower middle. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic